Prothena (PRTA) News Today $5.72 -0.03 (-0.52%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.83 +0.11 (+1.91%) As of 06/20/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Prothena (NASDAQ:PRTA) Earns Neutral Rating from Cantor FitzgeraldJune 21 at 1:57 AM | americanbankingnews.comProthena Corp (PRTA) Receives Reiterated Neutral Rating from Cantor Fitzgerald | PRTA Stock NewsJune 20 at 10:18 AM | gurufocus.comCantor Fitzgerald Reiterates "Neutral" Rating for Prothena (NASDAQ:PRTA)Cantor Fitzgerald restated a "neutral" rating on shares of Prothena in a research report on Friday.June 20 at 9:36 AM | marketbeat.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 19 at 1:10 AM | finance.yahoo.comProthena Announces Corporate RestructuringJune 18 at 4:51 PM | finance.yahoo.comProthena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average - Time to Sell?Prothena (NASDAQ:PRTA) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?June 18 at 3:29 AM | marketbeat.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 17, 2025 | msn.comProthena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | uk.finance.yahoo.comProthena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | businesswire.comProthena Co. plc (NASDAQ:PRTA) Short Interest Down 50.7% in MayProthena Co. plc (NASDAQ:PRTA - Get Free Report) was the target of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 4,410,000 shares, a drop of 50.7% from the May 15th total of 8,950,000 shares. Based on an average daily trading volume, of 1,350,000 shares, the days-to-cover ratio is currently 3.3 days. Currently, 10.4% of the company's stock are sold short.June 14, 2025 | marketbeat.comCantor Fitzgerald Forecasts Prothena FY2026 EarningsJune 11, 2025 | americanbankingnews.comCantor Fitzgerald Weighs in on Prothena FY2026 EarningsProthena Co. plc (NASDAQ:PRTA - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Prothena in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst C. Duncan expects that the biotechnology company will earn ($3.66) per sharJune 10, 2025 | marketbeat.comPRTA Prothena Corporation plcJune 7, 2025 | seekingalpha.comProthena Co. plc (NASDAQ:PRTA) Short Interest Up 20.1% in MayProthena Co. plc (NASDAQ:PRTA - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 8,950,000 shares, an increase of 20.1% from the April 30th total of 7,450,000 shares. Based on an average trading volume of 1,060,000 shares, the days-to-cover ratio is presently 8.4 days. Approximately 21.2% of the shares of the company are sold short.June 6, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in Prothena Co. plc (NASDAQ:PRTA)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 27.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 381,508 shareJune 3, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of "Hold" by BrokeragesProthena Co. plc (NASDAQ:PRTA - Get Free Report) has been assigned a consensus rating of "Hold" from the nine brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued aJune 1, 2025 | marketbeat.comFY2025 EPS Estimates for Prothena Cut by Chardan CapitalProthena Co. plc (NASDAQ:PRTA - Free Report) - Equities researchers at Chardan Capital reduced their FY2025 earnings per share (EPS) estimates for Prothena in a research note issued on Tuesday, May 27th. Chardan Capital analyst R. Li now anticipates that the biotechnology company will post earninMay 31, 2025 | marketbeat.comPiper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial DiscontinuationMay 30, 2025 | msn.comChardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial FailureMay 30, 2025 | msn.comH.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PTMay 30, 2025 | insidermonkey.comFY2027 EPS Estimates for Prothena Decreased by HC WainwrightProthena Co. plc (NASDAQ:PRTA - Free Report) - HC Wainwright dropped their FY2027 earnings per share estimates for shares of Prothena in a note issued to investors on Tuesday, May 27th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn ($5.44) per share for theMay 30, 2025 | marketbeat.comWellington Management Group LLP Increases Position in Prothena Co. plc (NASDAQ:PRTA)Wellington Management Group LLP increased its stake in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 22.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,130,876 shares of the biotechnology company'May 30, 2025 | marketbeat.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 30, 2025 | finance.yahoo.comB of A Securities Downgrades Prothena (PRTA)May 29, 2025 | msn.comProthena (NASDAQ:PRTA) Lowered to Underperform Rating by Bank of AmericaBank of America lowered shares of Prothena from a "neutral" rating to an "underperform" rating and set a $4.00 price target on the stock. in a research report on Wednesday.May 29, 2025 | marketbeat.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 29, 2025 | finance.yahoo.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 28, 2025 | insidermonkey.comPiper Sandler Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock PricePiper Sandler cut their price objective on Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research report on Tuesday.May 28, 2025 | marketbeat.comProthena Target of Unusually High Options Trading (NASDAQ:PRTA)Prothena Co. plc (NASDAQ:PRTA - Get Free Report) saw unusually large options trading activity on Tuesday. Traders purchased 8,185 put options on the stock. This represents an increase of approximately 1,210% compared to the average volume of 625 put options.May 28, 2025 | marketbeat.comJMP Securities Cuts Prothena (NASDAQ:PRTA) Price Target to $29.00JMP Securities decreased their price objective on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating on the stock in a research report on Tuesday.May 28, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Downgraded by Cantor Fitzgerald to NeutralCantor Fitzgerald downgraded Prothena from an "overweight" rating to a "neutral" rating in a research note on Tuesday.May 28, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Downgraded by Jefferies Financial Group to HoldJefferies Financial Group lowered Prothena from a "buy" rating to a "hold" rating and set a $6.00 target price on the stock. in a research report on Tuesday.May 28, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Cut to Market Perform at OppenheimerOppenheimer downgraded shares of Prothena from an "outperform" rating to a "market perform" rating in a research report on Tuesday.May 28, 2025 | marketbeat.comChardan Capital Lowers Prothena (NASDAQ:PRTA) Price Target to $18.00Chardan Capital decreased their target price on Prothena from $40.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday.May 28, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock PriceHC Wainwright lowered their target price on shares of Prothena from $30.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday.May 28, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Prothena (PRTA) and Bristol-Myers Squibb (BMY)May 28, 2025 | theglobeandmail.comPeninsula biotech Prothena falters — again — and layoffs are on the wayMay 27, 2025 | bizjournals.comProthena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In PlaceMay 27, 2025 | seekingalpha.comProthena hits 52-week low amid downgrades after late-stage trial setbackMay 27, 2025 | msn.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 27, 2025 | insidermonkey.comWhy Is Prothena Stock Trading Lower On Tuesday?May 27, 2025 | benzinga.comDeutsche Bank AG Purchases 63,512 Shares of Prothena Co. plc (NASDAQ:PRTA)Deutsche Bank AG raised its position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 195.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,970 shares of the biotechnology company's stock after acqMay 26, 2025 | marketbeat.comProthena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary EndpointMay 23, 2025 | businesswire.comBNP Paribas Financial Markets Purchases 41,541 Shares of Prothena Co. plc (NASDAQ:PRTA)BNP Paribas Financial Markets lifted its holdings in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 74.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 97,383 shares of the biotechnology company's stock after purchasing anMay 22, 2025 | marketbeat.comBalyasny Asset Management L.P. Makes New $527,000 Investment in Prothena Co. plc (NASDAQ:PRTA)Balyasny Asset Management L.P. acquired a new position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 38,021 shares of the biotechnology companyMay 18, 2025 | marketbeat.comCantor Fitzgerald Upgrades Prothena (NASDAQ:PRTA) to "Strong-Buy"Cantor Fitzgerald upgraded Prothena to a "strong-buy" rating in a research report on Tuesday.May 17, 2025 | marketbeat.comProsight Management LP Sells 65,345 Shares of Prothena Co. plc (NASDAQ:PRTA)Prosight Management LP lessened its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 13.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 418,122 shares of the biotechnology company's stock after sellMay 17, 2025 | marketbeat.comProthena Shareholders Approve Key Amendments at AGMMay 16, 2025 | tipranks.comCantor Fitzgerald Expects Increased Earnings for ProthenaProthena Co. plc (NASDAQ:PRTA - Free Report) - Equities researchers at Cantor Fitzgerald upped their FY2025 EPS estimates for shares of Prothena in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology company will post earnings of ($May 16, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Issues Quarterly Earnings ResultsProthena (NASDAQ:PRTA - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The business had revenue of $2.83 million during the quarter, compared to analysts' expectations of $8.18 million. During the same period in the prior year, the firm posted ($1.34) EPS. Prothena's revenue for the quarter was up 5500.0% compared to the same quarter last year.May 12, 2025 | marketbeat.com Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTA Media Mentions By Week PRTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRTA News Sentiment▼0.440.65▲Average Medical News Sentiment PRTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRTA Articles This Week▼104▲PRTA Articles Average Week Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) News Today Structure Therapeutics News Today Enliven Therapeutics News Today Aurinia Pharmaceuticals News Today Niagen Bioscience News Today Wave Life Sciences News Today Spyre Therapeutics News Today CorMedix News Today Phibro Animal Health News Today Arcus Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRTA) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
